We are breaking the boundaries of standard therapeutic approaches. Our drug candidates aim to revolutionize the treatment of Parkinson’s disease and other neurodegenerative diseases, and of secondary lymphedema
Read moreOur novel drug candidate CDNF has the potential to stop the progression of Parkinson’s disease by protecting neurons from degeneration and by restoring their functions.
Learn moreLymfactin® aims at being the first curative treatment of secondary lymphedema caused by injuries of the lymphatic system.
Learn moreNecessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.